Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor – evidence for dosing flexibility
Authors:
- R. D. LeeRLR. D. Lee
- M. VakilyMVM. Vakily
- D. MulfordDMD. Mulford
- J. WuJWJ. Wu
- S. N. AtkinsonSAS. N. Atkinson
- 19 March 2009
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 29 (8) , 824-833
Abstract
Summary: Background Dexlansoprazole MR is a proton pump inhibitor with a Dual Delayed Release (DDR) formulation designed to prolong the dexlansoprazole plasma concentration–time profile. The presence of food or time of dosing relative to food may affect dexlansoprazole absorption.Aims To evaluate the effect of food on the pharmacokinetics (PK) and pharmacodynamics (PD) of dexlansoprazole following oral administration of dexlansoprazole MR.Methods In this open‐label, single‐dose, randomized, 4‐way crossover study, 48 healthy subjects received placebo (day 1) and dexlansoprazole MR 90 mg (day 3) after fasting, 5 or 30 min before a high‐fat breakfast, or 30 min after a high‐fat breakfast. Intragastric pH (days 1 and 3) and PK (day 3) of dexlansoprazole were assessed over a 24‐h interval after each dose.Results Following administration of dexlansoprazole MR under fasted/fed conditions, mean dexlansoprazole plasma concentration–time profiles generally exhibited two distinct peaks, resulting from the DDR formulation. Increases in dexlansoprazole maximum plasma concentration (12–31%) and area under the plasma concentration–time curve (9–21%) were observed with the fed regimens; however, differences in intragastric pH were not considered clinically relevant.Conclusion Dexlansoprazole MR can be administered without regard to food or the timing of food in most patients.Keywords
This publication has 10 references indexed in Scilit:
- Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed‐release formulation – results from two randomized controlled studiesAlimentary Pharmacology & Therapeutics, 2009
- Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazoleBritish Journal of Clinical Pharmacology, 2007
- Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitisAlimentary Pharmacology & Therapeutics, 2006
- Primary-Care Physicians' Perceptions and Practices on the Management of GERD: Results of a National SurveyAmerican Journal of Gastroenterology, 2005
- Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux DiseaseAmerican Journal of Gastroenterology, 2005
- Bioavailability and Bioequivalence of??Two Enteric-Coated Formulations of??Omeprazole in Fasting and Fed ConditionsClinical Drug Investigation, 2005
- Proton Pump Inhibitors and Acid‐Related DiseasesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997
- The Pharmacology of the Gastric Acid Pump: The H+,K+ ATPaseAnnual Review of Pharmacology and Toxicology, 1995
- Decreased Oral Bioavailability of Lansoprazole in Healthy Volunteers when Given with a Standardised BreakfastClinical Drug Investigation, 1995
- Appropriate Acid Suppression for the Management of Gastro-Oesophageal Reflux DiseaseDigestion, 1992